CLINICOPATHOLOGICAL STUDY OF BREAST CANCER AND IMMUNOHISTOCHEMICAL EXPRESSION OF BRCA 1 AND BRCA2 – A PROSPECTIVE STUDY

Author:

Perugu Naveen chandORCID,Komanapalli Sunilkumar,Kuna RajaniORCID,CHOWDARI BALAJI,DEVI URMILA,Das BasumitraORCID

Abstract

Objectives: The aim of this study was to study morphological features of breast cancer (BRCA), to grade according to Nottingham’s modification of Bloom Richardson (BR) grading system and to detect the immunohistochemical (IHC) expression of BRCA 1 and BRCA 2 proteins among the clinicopathological parameters of BRCA as age, menopausal status, tumor size, histopathological grade, and lymphnode status. Methods: This is a prospective and observational study conducted in the Department of Pathology from January 2015 to October 2016, Histopathological examination of 79 cases of Breast carcinoma was conducted and IHC using BRCA 1 and BRCA2 was done in 40 cases. Results: Out of 79 invasive breast carcinoma, the most common age group for breast carcinoma was 40–49 (40.5%) years. The most common histological subtype was invasive carcinoma-NST, 77(97.4%) cases. Forty cases studied for both BRCA-1 and BRCA 2 expression, regarding BRCA-1 expression, 11 cases showed score 1, 19 cases were of score 2, and eight cases belonged to score 3. Two cases did not show any expression. A positive statistical correlation existed between the size of the tumor, modified BR grade of tumor with BRCA-1 expression. Regarding BRCA-2 expression, 12 cases showed score 1, 17 cases was of score 2, and 10 cases belonged to score 3. One case did not show any expression. Conclusion: BRCA gene participates in the pathogenesis of breast carcinomas. It is an indicator of poor prognosis. BRCA positivity decreased with increase in age, size of tumor, lymphnodes showing metastasis, and higher grade of the tumor. The present study indicates that BRCA is a powerful predictor of prognosis.

Publisher

Innovare Academic Sciences Pvt Ltd

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference20 articles.

1. Lester SC. The breast. In: Robins and Cotran Pathologic Basis of Disease. 9th ed. Amsterdam: Elsevier; ???. p. 1051.

2. Charles Brunicardi F. Breast ‘Schwartz’s Principles of Surgery’. 9th ed. Philadelphia PA, Lippincott Williams and Wilkins; 2009. p. 440-1.

3. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1-or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 1999;85:2200- 5. doi: 10.1002/(SICI)1097-0142(19990515)85:10<2200:AID-CNCR14>3.0.CO;2-S, PMID 10326698

4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, editors. GLOBOCAN 2008v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer. Available from: https://globocan.iarc.fr

5. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992;2:128-31. doi: 10.1038/ng1092- 128, PMID 1303261

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3